Powder for solution or suspension for injection
Cefuroxime
Biofuroxym is an antibiotic used in adults and children. The medicine works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.
Biofuroxym is also used:
➔
If you think any of these apply to you, tell your doctor before taking Biofuroxym. You should not take Biofuroxym.
While taking Biofuroxym, pay attention to whether you experience any symptoms such as allergic reactions and stomach or gut disorders (e.g. diarrhea). This will reduce the risk of complications (see "Symptoms to watch out for" in section 4). If you have had an allergic reaction to other antibiotics, such as penicillin, you may also be allergic to Biofuroxym.
Severe skin reactions have been reported with cefuroxime, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS). If you notice any of the symptoms of severe skin reactions described in section 4, seek medical attention immediately.
Biofuroxym may affect the results of tests for sugar in the urine or blood, or a blood test called the Coombs test. If you are going to have these tests, you should:
➔
tell the person taking the samplethat you are taking Biofuroxym.
Tell your doctor about all the medicines you are taking now or have recently taken, including those that are available without a prescription.
Some medicines may affect the action of Biofuroxym or increase the risk of side effects. These include:
Tell your doctor before taking Biofuroxym:
Your doctor will assess whether the benefits of taking Biofuroxym during pregnancy and breastfeeding outweigh the risks to the baby.
Do not drive or operate machinery if you do not feel well.
Biofuroxym, 250 mg
The medicine contains 14 mg of sodium (a major component of common salt) per vial. This corresponds to 0.7% of the maximum recommended daily intake of sodium in the diet for adults.
Biofuroxym, 500 mg
The medicine contains 28 mg of sodium (a major component of common salt) per vial. This corresponds to 1.4% of the maximum recommended daily intake of sodium in the diet for adults.
Biofuroxym, 750 mg
The medicine contains 42 mg of sodium (a major component of common salt) per vial. This corresponds to 2.1% of the maximum recommended daily intake of sodium in the diet for adults.
Preparation of the medicine for administration - see section "Information intended for healthcare professionals only" at the end of the package leaflet. When calculating the total sodium content in the prepared dilution, consider the sodium from the diluent. For accurate information on the sodium content in the solution used for dilution, refer to the patient information leaflet of the diluent used.
Consider this for patients controlling their sodium intake.
Biofuroxym is usually given by a doctor or nurse. It can be given by drip (intravenous infusion)or as an injectiondirectly into a vein or muscle.
Your doctor will decide the correct dose of Biofuroxym for you, taking into account the severity and type of infection, any other antibiotics you are taking, your body weight, age, and kidney function.
For every kilogram of the infant's body weight, a dose of 30 to 100 mg of Biofuroxym is given over 24 hours, divided into two or three doses.
For every kilogram of the infant's or child's body weight, a dose of 30 to 100 mg of Biofuroxym is given over 24 hours, divided into three or four doses.
From 750 mg to 1.5 g of Biofuroxym, two, three, or four times a day. No more than 6 g per day.
If you have kidney problems, your doctor may change the dose of Biofuroxym.
➔
If this applies to you, tell your doctor.
Like all medicines, Biofuroxym can cause side effects, although not everybody gets them.
A small number of people taking Biofuroxym have reported an allergic reaction or potentially severe skin reaction. Their symptoms may be:
Severe allergic reaction. Symptoms include: raised, itchy rash, swelling, sometimes of the face or mouth, which can make breathing difficult.
➔
Common side effects(occurring in less than 1 in 10 patients):
Common side effects that may appear in blood test results:
Uncommon side effects(occurring in less than 1 in 100 patients):
Uncommon side effects that may appear in blood test results:
Other side effects occur in a very small number of patients, but the frequency cannot be estimated from the available data (the frequency cannot be determined from the available data):
➔
If you experience any of the above side effects, tell your doctor.
Side effects that may appear in blood test results:
If you experience any side effects, including any not listed in this leaflet, please tell your doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.
Keep the medicine out of the sight and reach of children.
Store the medicine at a temperature below 25°C, away from light.
After reconstitution, the solution remains stable for 24 hours at a temperature between 2°C and 8°C.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
The notation on the packaging after the abbreviation EXP means the expiry date, and after the abbreviation Lot means the batch number.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The medicine is a white or almost white, crystalline powder in a glass vial containing 250 mg, 500 mg, or 750 mg of powder. The vials are closed with a rubber stopper and protected with an aluminum cap or an aluminum cap with a hood, and packaged in cardboard boxes.
The pack contains 1 or 10 vials.
Not all pack sizes may be marketed.
Pharmaceutical Works POLPHARMA S.A.
ul. Pelplińska 19
83-200 Starogard Gdański
phone: +48 22 364 61 01
Pharmaceutical Works POLPHARMA S.A.
ul. Pelplińska 19
83-200 Starogard Gdański
Pharmaceutical Works POLPHARMA S.A.
Production Plant in Duchnice
ul. Ożarowska 28/30
05-850 Ożarów Mazowiecki
Table 1. Volumes of water to be added and concentrations of the solution useful when partial doses are to be used.
Vial size | Route of administration | Volume of water to be added | Approximate concentration of cefuroxime** |
250 mg | intramuscularly | 1 ml | 216 mg/ml |
intravenously | at least 2 ml | 116 mg/ml | |
500 mg | intramuscularly | 2 ml | 216 mg/ml |
intravenously | 4 ml | 116 mg/ml | |
750 mg | intramuscularly | 3 ml | 216 mg/ml |
intravenous injection | at least 6 ml | 116 mg/ml | |
intravenous infusion | at least 6 ml | 116 mg/ml |
** The resulting volume of the cefuroxime solution in the solvent increases due to the phase shift coefficient of the active substance, resulting in the presented concentrations (mg/ml).
Compatibility
Cefuroxime sodium (5 mg/ml) in 5% w/v or 10% w/v xylitol injection solution can be stored for up to 24 hours at 25°C.
Cefuroxime sodium is compatible with aqueous solutions containing no more than 1% lidocaine hydrochloride.
Cefuroxime sodium is compatible with the following infusion solutions, with which its action is maintained for 24 hours at room temperature:
0.9% w/v sodium chloride solution
5% glucose solution for injection
0.18% w/v sodium chloride solution with 4% glucose solution for injection
5% glucose solution and 0.9% sodium chloride solution for injection
5% glucose solution and 0.45% sodium chloride solution for injection
5% glucose solution and 0.225% sodium chloride solution for injection
10% glucose solution for injection
10% invert sugar solution in water for injection
Ringer's solution for injection
Lactated Ringer's solution for injection
Sodium lactate solution for injection (M/6)
Multicomponent sodium lactate solution for injection (Hartmann's solution).
The stability of cefuroxime sodium in 0.9% sodium chloride solution for injection and in 5% glucose solution for injection is not affected by the presence of sodium hydrocortisone phosphate.
Cefuroxime sodium also shows compatibility for 24 hours at room temperature if added to an intravenous infusion solution containing:
heparin (10 or 50 units/ml) in 0.9% sodium chloride solution for injection;
potassium chloride (10 or 40 mEq/l) in 0.9% sodium chloride solution for injection.
Any unused product or waste material should be disposed of in accordance with local regulations.
Preparation of the solution for rapid injection
Puncture the stopper with a needle and inject the recommended volume of solvent into the vial. To puncture the stopper, use a needle with a diameter not greater than 0.8 mm. Insert the needle into the center of the stopper at a 90° angle, as shown in the following diagram:
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.